GAMMA Investing LLC Purchases 491,488 Shares of DexCom, Inc. (NASDAQ:DXCM)

GAMMA Investing LLC raised its stake in shares of DexCom, Inc. (NASDAQ:DXCM - Free Report) by 5,951.7% in the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 499,746 shares of the medical device company's stock after acquiring an additional 491,488 shares during the quarter. GAMMA Investing LLC owned approximately 0.13% of DexCom worth $34,128,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Private Trust Co. NA raised its holdings in shares of DexCom by 266.3% in the fourth quarter. Private Trust Co. NA now owns 337 shares of the medical device company's stock valued at $26,000 after buying an additional 245 shares during the last quarter. Optiver Holding B.V. bought a new stake in DexCom during the 4th quarter worth about $33,000. TD Private Client Wealth LLC grew its position in shares of DexCom by 62.8% during the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company's stock worth $34,000 after buying an additional 167 shares during the period. Larson Financial Group LLC grew its position in shares of DexCom by 40.5% during the 4th quarter. Larson Financial Group LLC now owns 475 shares of the medical device company's stock worth $37,000 after buying an additional 137 shares during the period. Finally, Heck Capital Advisors LLC acquired a new position in shares of DexCom during the 4th quarter worth about $38,000. 97.75% of the stock is owned by institutional investors.

Analysts Set New Price Targets

DXCM has been the subject of several research analyst reports. Wall Street Zen upgraded DexCom from a "hold" rating to a "buy" rating in a research report on Friday. Cfra Research upgraded DexCom to a "hold" rating in a research note on Friday, March 21st. Canaccord Genuity Group upped their price objective on DexCom from $103.00 to $106.00 and gave the stock a "buy" rating in a research note on Friday, May 2nd. Piper Sandler dropped their target price on DexCom from $100.00 to $90.00 and set an "overweight" rating for the company in a report on Friday, May 2nd. Finally, Morgan Stanley lifted their target price on DexCom from $75.00 to $82.00 and gave the stock an "equal weight" rating in a report on Friday, February 14th. Four research analysts have rated the stock with a hold rating, fifteen have assigned a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, DexCom currently has an average rating of "Moderate Buy" and an average price target of $98.32.

DexCom Trading Up 1.1%

Shares of DexCom stock traded up $0.93 during midday trading on Friday, reaching $86.67. The company had a trading volume of 2,422,601 shares, compared to its average volume of 4,340,357. The stock has a fifty day moving average price of $76.38 and a 200 day moving average price of $79.04. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The firm has a market cap of $33.98 billion, a PE ratio of 60.61, a P/E/G ratio of 2.30 and a beta of 1.46. DexCom, Inc. has a fifty-two week low of $57.52 and a fifty-two week high of $118.80.

DexCom (NASDAQ:DXCM - Get Free Report) last issued its quarterly earnings results on Thursday, May 1st. The medical device company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a net margin of 14.29% and a return on equity of 30.14%. The business had revenue of $1.04 billion during the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the firm posted $0.32 earnings per share. DexCom's quarterly revenue was up 12.5% compared to the same quarter last year. On average, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Insider Activity

In other news, CEO Kevin R. Sayer sold 32,498 shares of the business's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $2,287,209.24. Following the completion of the sale, the chief executive officer now owns 372,029 shares in the company, valued at $26,183,401.02. The trade was a 8.03% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, EVP Jereme M. Sylvain sold 7,000 shares of the company's stock in a transaction on Monday, March 10th. The stock was sold at an average price of $73.83, for a total transaction of $516,810.00. Following the completion of the sale, the executive vice president now owns 135,482 shares of the company's stock, valued at approximately $10,002,636.06. The trade was a 4.91% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 83,110 shares of company stock worth $6,103,505 over the last quarter. 0.32% of the stock is currently owned by corporate insiders.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.